Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report

Giacomo Puppa1, Makio Shozu2, Tiziana Perin1, Kazuhito Nomura3, Annunziata Gloghini4, Elio Campagnutta5 and Vincenzo Canzonieri*1

Address: 1Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori – IRCCS, Via Pedemontana Occidentale 12, 33081 Aviano PN, Italy, 2Graduate School of Chiba University, Reproductive Medicine, Chuo-ku, Chiba, Japan, 3Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Takara-machi, Kanazawa, Japan, 4Diagnostic Immunohistochemistry and Molecular Pathology Unit, Istituto Nazionale Tumori – IRCCS, Aviano PN, Italy and 5Division of Gynecologic Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori – IRCCS, Aviano PN, Italy

Email: Giacomo Puppa - gpuppa@yahoo.com; Makio Shozu - shozu@faculty.chiba-u.jp; Tiziana Perin - tperin@cro.it; Kazuhito Nomura - nomura@med.kanazawa-u.ac.jp; Annunziata Gloghini - agloghini@cro.it; Elio Campagnutta - ecampagnutta@cro.it; Vincenzo Canzonieri* - vcanzonieri@cro.it

* Corresponding author

Abstract

Background: Malignant transformation of adenomyosis is a very rare event. Only about 30 cases of this occurrence have been documented till now.

Case presentation: The patient was a 57-year-old woman with a slightly enlarged uterus, who underwent total hysterectomy and unilateral adnexectomy. On gross inspection, the uterine wall displayed a single nodule measuring 5 cm and several small gelatinous lesions. Microscopic examination revealed a common leiomyoma and multiple adenomyotic foci. A few of these glands were transformed into a moderately differentiated adenocarcinoma. The endometrium was completely examined and tumor free. The carcinoma was, therefore, considered to be an endometrioid adenocarcinoma arising from adenomyosis. Four months later, an ultrasound scan revealed enlarged pelvic lymph nodes: a cytological diagnosis of metastatic adenocarcinoma was made.

Immunohistochemical studies showed an enhanced positivity of the tumor site together with the neighbouring adenomyotic foci for estrogen receptors, aromatase, p53 and COX-2 expression when compared to the distant adenomyotic glands and the endometrium. We therefore postulate that the neoplastic transformation of adenomyosis implies an early carcinogenic event involving p53 and COX-2; further tumor growth is sustained by an autocrine-paracrine loop, based on a modulation of hormone receptors as well as aromatase and COX-2 local expression.

Conclusion: Adenocarcinoma in adenomyosis may be affected by local hormonal influence and, despite its small size, may metastasize.
Background
Leiomyoma and adenomyosis are both commonly encountered in hysterectomy surgical specimens, often as incidental findings. A frequent association of adenomyosis with other hormone-dependent uterine lesions, both benign and malignant, such as endometrial hyperplasia, endometrial carcinoma and leiomyoma has already been described in the literature [1,2]. However, the development of cancer from adenomyosis is a relatively rare occurrence. In all cases, the following Sampson's criteria should be fulfilled to confirm the malignant transformation:

1) evidence of pre-existing endometriosis at the site of the supposed malignant lesion;

2) exclusion of the possibility of the carcinoma representing an invasion or metastasis from another location;

3) evidence of transitions between the benign and malignant glandular structures; and

4) both glands and stroma must be present to constitute genuine adenomyosis [3].

At present, only about 30 cases of adenocarcinoma arising from adenomyosis without endometrial malignancy have been reported in the English literature [4-12]. In all these cases, the immunohistochemical studies were of limited extent and the few cases reported with immunohistochemistry were all negative for ER [6,9,12].

We report on the clinico-pathological and immunohistochemical findings of a small endometrioid adenocarcinoma arising from adenomyosis, incidentally discovered around a leiomyoma after extensive sampling. To the best of our knowledge, this is the single smallest reported instance of such an occurrence with a distinct immunohistochemical profile. The possible connection between malignant transformation of adenomyosis and benign, hormone-dependent disease is discussed.

Case presentation
Clinical summary
The patient was a 57-year-old nulliparous, asymptomatic woman of normal weight. She was in follow-up for a fibromatous uterus. On palpation, a uterine softening was noted. An ultrasound scan displayed the enlargement of a pre-existent leiomyomatous nodule and multiple minute focal lesions throughout the uterine wall, diagnosed as a likely adenomyosis. Menopause had commenced at the age of 54. Her past medical history was significant for papillary serous cystadenoma of the left ovary which was removed when she was 33 years of age. For the last few years, the patient was being treated with an antihypertensive therapy, while, nine years previously, for a period of two years, she had taken symptomatic therapy for perimenopausal symptoms including progesterone, and, during the last year, a non-hormonal therapy with a hyperprolactinemic effect to reduce hot flushes.

Because of the recent appearance of focal lesions in the uterine corpus in an already enlarged uterus (as seen on the ultrasound scan), a total hysterectomy and unilateral adnexectomy were performed. Four months later, an ultrasound scan revealed an enlargement of the left external iliac chain nodes and a thickening of the lateral pelvic wall up to the inguinal ring. A second-look surgical inspection as well as an extensive clinical work-up, which included a thoraco-abdominal CT scan, excluded the presence of other primary tumors.

Methods
The tissues were fixed in Bouin solution and embedded in paraffin for histologic processing. Tissue sections were stained with hematoxylin and eosin for conventional histology. Immunohistochemical stainings were performed using a combination of the avidin-biotin complex peroxidase method (ABC kit; Vector Laboratories, Burlingham, CA, USA) and microwave antigen retrieval with the following antibodies: ER (Clone 6F11, Novocastra, Newcastle, UK); PR (Clone Pgr636 Dakocytomation, Glostrup, Denmark); C-erb B2 (Clone A0485, polyclonal antibody Dakocytomation, Glostrup, Denmark); Cyclooxygenase-2 (COX-2) (clone 4H12, Novocastra, Newcastle, UK); p53 (Clone DO-7, Novocastra, Newcastle, UK) and CA125 (Clone Ov185:1, Novocastra, Newcastle, UK).

The sections were also stained for aromatase as follows: sections were dewaxed in xylene and taken through a graded series of ethanol. Epitope retrieval was performed by enzymatic digestion with trypsin for 20 minutes at 37°C (TRYPSIN Tablets; Sigma, St. Louis, MO, USA). After incubation with 0.3% hydrogen and protein block solution (DAKO) for 5 minutes, the sections were treated with polyclonal antiaromatase antibody (provided by Dr. Nobuhiro Harada, Ph.D., Fujita Health University, Nagoya, Japan) for 15 minutes at room temperature following dilution to 1:1,000 in buffer. After incubation with the primary antibody, streptavidin-biotin complex and streptavidin-peroxidase complex were applied for 15 minutes each at room temperature. Colour was developed by incubation with 3,3-diaminobenzidine-tetrahydrochloride for 1 min, followed by counterstaining with hematoxylin.

Negative controls included sections incubated with normal rabbit serum instead of the primary antibody. In
addition, an immunoabsorption test was done as follows:
a complex of 1 μl of anti-aromatase antibody and 1.5 μl of
microsome (at a concentration of 4 μg/μl), extracted from
placental tissue, was stirred in phosphate buffer saline
containing 1% bovine serum albumin for 12 hours at
4°C, and the resulting precipitate was then centrifuged
(10,000 g for 1 hour). Instead of the primary antibody,
the supernatant was used for immunostaining.

Pathological findings
On gross examination, the uterus measured 7 × 4 × 9 cm
and the right ovary measured 3 cm. On cut section, the
myometrium of the fundus presented a subserosal
whorled leiomyomatous nodule which measured 5 cm,
was well circumscribed, solid and surrounded by gelati-
nous foci. The endometrium appeared thinned with no
superficial irregularities. It was totally examined, and only
atrophic-cystic changes with focal proliferative activity
were seen. There were several adenomyotic foci in the
inner half of the myometrium, while some others, in the
outer half, were pushed out by the leiomyoma and were
located proximally to the serosa and parametrium. A clus-
ter of these glands harboured a focal malignant transfor-
mation of the epithelial component, diagnosed as
moderately differentiated endometrioid adenocarcinoma
measuring 0.8 cm (Figures 1A and 1B) associated with
atypical hyperplasia. The tumor was considered invasive
because of the presence of solid areas with the confluence
of neoplastic glands uninterrupted by stroma.

The enlarged iliac lymph nodes, detected 4 months after
surgery, were biopsied by fine-needle aspiration during a
second-look procedure, and were diagnosed as metastatic
adenocarcinoma (Figure 1C).

Immunohistochemically, the primary tumor displayed
strong positivity for ER, PR, COX-2, CA125 and focal posi-
tivity for p53 and aromatase (Figures 2A–F). The leiomy-
oma was positive for ER, PR, weakly positive for COX-2
and negative for p53 and CA125. The primary tumor was
negative for C-erb B2. In both the eutopic and ectopic
endometrial glands, the positivity for PR was diffuse,
whereas an alternation of positive and negative foci were
noted for ER, aromatase and p53 (Figures 3A–D). In par-
ticular, we noted a tendency of the endometrial glands to
be negative for ER in the atrophic areas and positive in the
proliferative component (Figure 3A). The cell block cytol-
ogy of the lymph node metastasis was positive for Cytok-
eratins AE1/AE3, ER, PR, CA125, p53 and COX-2 (Figure
1D, only CA125 shown).

Conclusion
The case that we present is a single, small, moderately dif-
ferentiated endometrioid adenocarcinoma which devel-
oped into adenomyosis with subsequent metastatic
spread to the iliac lymph nodes. The primary tumor was
positive for ER, PR, COX-2, CA125, p53 and focally weak-
positive for aromatase. Malignant transformation of ade-
nomyotic foci is per se a rare event, but the development
of metastatic lymph nodal deposits from a very small pri-
mary adenomyotic adenocarcinoma is quite exceptional.

The diagnosis of malignant tumors in adenomyosis is
usually made in an advanced stage of disease when the
neoplasm has grown in nodules within the uterine wall or
has involved the endometrium causing abnormal uterine
bleeding and/or has spread out of the uterus [5,7-9,12].

In 1925, Sampson introduced the histological criteria to
define an adenocarcinoma arising in external endometri-
osis, which can be adapted to adenomyosis [3].

In the literature, the clinico-pathological findings of 8
cases of adenocarcinoma arising in adenomyosis were
presented by Hernandez and Woodruff in 1980, but these
were all associated with endometrial adenocarcinomas.
They also evaluated 16 cases previously reported by other
authors in the literature, and found that only 8 of these
were not associated with endometrial adenocarcinomas
[5]. In the few cases described as small or microscopic
tumors, the pathology report did not include the number
or the diameter of the largest tumor, mentioning only that
the inner or the outer part of the uterine wall was involved
[5,11].

It is well known that gynaecological malignancies, includ-
ing breast, ovarian and uterine carcinomas, are influenced

Figure 1
(A) The tumor arises from the confluence of transformed
foci. (B) Higher power magnification of the tumor. (C) Cell
block cytology of the lymph node metastasis. (D) Immunocy-
tochemical staining of the metastasis for CA125.
by hormonal stimulation. In the uterus, a peculiar hormon-
als microenvironment may explain different pathologic condi-
tions, both benign and malignant. The complex inter-
relationships between adenomyosis, endometriosis, 
leiomyomata, endometrial hyperplasia and carcinoma 
 arising in the endometrium or in adenomyosis have been 
illustrated together with their hormonal dependency 
[1,2,13], and factors like obesity and hormonal replace-
ment therapy have been considered as relevant risk factors 
[13,14].

In postmenopausal women, estrogen formation is 
ensured by extraglandular tissues, namely adipose tissue 
and skin. Endometriosis and leiomyomas constitute two 
added sources of aberrant estrogen biosynthesis, prima-
rily by aromatase enzymatic activity, promoting their self-
stimulation [15,16]. Aromatase detection has already 
been proposed as a test for endometriosis in endometrial 
biopsies because aromatase cytochrome P450 is expressed 
in the eutopic endometrium of patients with endometriosis 
but not in those of disease-free women [17].

In endometriosis, aromatase activity is stimulated by 
prostaglandin E(2) which, in turn, is up-regulated by 
increased levels of the enzyme cyclo-oxygenase-2 (COX-
2) [18].

Finally, besides aberrant aromatase expression, a local 
estrogen overproduction in endometriosis may also be a 
result of a deficiency of 17β-hydroxysteroid dehydroge-
nase, resulting in failure to metabolize 17β-Estradiol [19].

In three studies, adenocarcinomas in adenomyosis were 
reported as all negative for ER and fairly negative for PR 
[6,9,12]. The reported cases in these small series were 
rather advanced. Therefore, the hormone receptor and C-
erb B2 status in our case of moderately differentiated ade-
nocarcinoma is indicative of early tumor development, 
similar to that observed in correspondent neoplasms 
arisen in the eutopic endometrium where hormonal 
receptor positivity and C-erb B2 negativity are most often 
associated with low grade and early-stage tumors [20,21].
A peculiar observation in our case is the alternation of 
positive and negative areas for ER, aromatase and COX-2 
in both the normal and the pathological tissues, including 
the endometrium and the adenomyotic foci. This heterog-
enous, "checker-board-like" expression of steroid recep-
tors and enzymes involved in steroidogenesis suggests

Figure 2
(A) Diffuse strong positivity for ER of the tumor. (B) Patchy positivity for PR of the tumor. (C) Aromatase positivity of benign adenomyotic foci (arrows). Most neoplastic cells are negative for aromatase (asterisk) except for some glands (insert). (D) COX-2 positivity of the tumor and adenomyosis. (E) CA125 positivity of the tumor and of the adenomyotic epithelium. (F) Focal positivity for p53 of the tumor.
firstly that there are different fields of hormonal responsiveness, and secondly, that the endometriosis derives from, and is in phase with, the endometrium [22].

COX-2 overexpression has been described in ectopic endometriosis implants when compared with eutopic endometrium [23], in endometrial carcinoma where it is associated with several parameters of tumor aggressiveness [24,25], and in endometriosis-associated ovarian carcinoma [26].

Moreover, COX-2 has been suggested to be involved in multiple steps in endometrial cancer: besides tumor progression, the enzyme has been implicated in the earlier phases of neoplastic transformation, in endometrial hyperplasia [27] and in endometriosis-associated ovarian carcinoma [26].

Accordingly, we found an enhanced positivity for COX-2 both in the tumor and in the neighbouring adenomyotic foci, when compared to the distant adenomyosis and the endometrium.

P53 has been showed to be expressed in endometrial carcinoma with and without adenomyosis [29], in other cases of adenocarcinoma arising from uterine adenomyosis without endometrial malignancy [6,9], but also in hyperplastic and atypical epithelia of carcinoma-associated adenomyosis [29] and in endometrial carcinoma without myometrial invasion [30]. Therefore, an early involvement of p53 in endometrial carcinoma and in the malignant transformation of adenomyosis has been suggested [29, 30]. In the case we present here, p53 positivity was observed in the benign adenomyotic glands, in the atypical hyperplasia and in the neoplasm itself, lending support to the proposed model of carcinogenesis in adenomyosis.

Our case is quite peculiar for the early metastatic spread to the iliac lymph nodes, confirmed by cytological fine-needle aspiration performed during the second-look surgical inspection and by an extensive clinical work-up to exclude other sites of primaries. The origin of the metastasis from adenocarcinoma in adenomyosis was also confirmed by its immunocytochemical profile. A possible explanation for such early metastatic spreading is that this tumor arose in the outer myometrium, near to the richly vascularized parametrium.

In conclusion, considering that no evidence of systemic exogenous or endogenous hyperestrogenism are on record in our case, it is arguable that the presence of a leiomyoma, close to a pool of adenomyotic foci, along with the overexpression of estrogen receptors and enzymes involved in steroidogenesis, represent a hyperestrogenic microenvironment with converging sources of estrogen biosynthesis. Therefore, the same local estrogen excess, besides sustaining adenomyosis and leiomyoma persistence, may also promote growth in tumors having adequate ER/PR expression. This local hormonal overproduction most likely interacts with other events, such as p53 mutations and COX-2 increased activity, in the pathogenesis of adenocarcinoma in adenomyosis.

Abbreviations
ER: estrogen receptors; PR: progesterone receptors.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
GP conceived and coordinated the study and drafted the manuscript. MS was responsible for the immunohistochemical staining with aromatase and revised the manuscript for important intellectual content. TP was responsible for the sampling of the surgical specimen. KN was responsible for the immunohistochemical staining with aromatase. AG was responsible for the immunohistochemical staining with ER, PR, C-erb B2 and COX-2. EC was responsible for performance of all the surgical interventions. VC participated in the coordination of the study and revised the manuscript for important intellectual content. All the authors approved the final manuscript.
Acknowledgements

The authors gratefully thank Mrs. Anna Maria Colussi for her assistance with the editing of the text.

Written consent was obtained from the patient for publication of the study.

References

1. Koshiyama M, Okamoto T, Ueta M: The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detect Prev 2004, 28:94-101.

2. Marcus CC: Relationship of adenomyosis uteri to endometrial hyperplasia and endometrial carcinoma. Am J Obstet Gynecol 1961, 82:408-416.

3. Sampson JA: Endometrial carcinoma of the ovary arising in endometrial tissue of that organ. Archives of Surgery 1925, 10:1-72.

4. Couto D, Mota F, Silva T, Coelho F: Adenocarcinoma arising in adenomyosis: report of an unusual case. Acta Obstet Gynecol Scand 2001, 80:1308-1313.

5. Hernandez E, Woodruff JD: Endometrial adenocarcinoma arising in adenomyosis. Am J Obstet Gynecol 1980, 138:827-832.

6. Koshiyama M, Suzuki A, Ozawa M, Fujita K, Sakakibara A, Kawamura M, Takahashi S, Fujii H, Hirano T, Oikagaki A, Nagano T, Ban C: Adenocarcinoma arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol 2002, 21:239-245.

7. Kuwashima Y, Uehara T, Kishi K, Tajima H, Shiromizu K, Matsuzawa M, Takayama S: Intramural adenocarcinoma of the uterus, arisen from adenomyosis uteri, showing unique histologic appearance. Report of two cases. Eur J Obstet Gynecol Biol 1994, 15:418-423.

8. Rubo C, Narducci F, Delatrette C, Decoq J, Verbert A, Delahousse G: Endometrioid adenocarcinoma arising from adenomyosis. A case report and literature review. J Gynecol Obstet Biol Reprod (Paris) 2004, 33:140-144.

9. Sasaki T, Sugiyama T, Nonjo H, Hoshi N, Murakami M, Sugita A, Takahashi M, Kawamura K, Ono I, Masuda H: Endometrioid adenocarcinoma arising from adenomyosis: report and immunohistochemical analysis of an unusual case. Pathol Int 2001, 51:308-313.

10. Takai N, Akizuki S, Nasu K, Etoh Y, Miyakawa I: Endometrioid adenocarcinoma arising from adenomyosis. Gynecol Obstet Invest 1999, 48:141-144.

11. Woodruff JD, Erzaban YS, Genadry R: Adenocarcinoma arising in adenomyosis detected by atypical cytology. Obstet Gynecol 1986, 67:145-148.

12. Takeuchi K, Yamana Y, Hamana S, Ohara N, Maruo T: Invasive adenocarcinoma arising from uterine adenomyosis involving the rectosigmoid colon. Int J Gynecol Cancer 2004, 14:1004-1006.

13. Zanetta GM, Webb MJ, Li H, Keeney GL: Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol 2000, 79:18-22.

14. Giordano G, Gneetti L, Merisio C, Melpignano M: Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps. Maturitas 2007, 56:190-197.

15. Bulun SE, Emir G, Utsunomiya H, Thung S, Gurates B, Tamura M, Lin Z: Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005, 95:57-62.

16. Shozu M, Murakami K, Inoue M: Aromatase and leiomyoma of the uterus. Semin Reprod Med 2004, 22:51-60.

17. Kitawaki J, Kusuki I, Koshiba H, Tsukamoto K, Honjo H: Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis. Gynecol Obstet Invest 1999, 48 Suppl 1:21-28.

18. Attar E, Bulun SE: Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006, 12:49-56.

19. Zeitzou K, Takayama K, Sasano H, Suzuki T, Mughrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE: Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998, 83:4474-4480.

20. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000, 13:379-388.

21. Morrison C, Zaragoza V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM: HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006, 24:2376-2385.

22. Leyendecker G, Herbertz M, Kunz G, Mail G: Endometriosis results from the dissolution of basal endometrium. Hum Reprod 2002, 17:2725-2736.

23. Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M: Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002, 48:50-56.

24. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G, Lauriola L: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002, 95:801-807.

25. Li W, Xu RJ, Zhang HH, Jiang LH: Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. Int J Gynecol Cancer 2006, 16:1673-1678.

26. Chou YC, Chen YJ, Lai CR, Wang PH, Hsin C, Yuan CC: Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis. Eur J Obstet Gynecol Biol Reprod 2006, 124:101-105.

27. Orejuela FJ, Ramondetta LM, Smith J, Brown J, Lemos LB, Li Y, Hollier LM: Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol 2005, 97:483-488.

28. Taskin M, Lallas TA, Shevchuk M, Barber HR: P53 expression in adenomyosis in endometrial carcinoma patients. Gynecol Oncol 1996, 62:241-246.

29. Koshiyama M, Konishi I, Wang DP, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Naito MF, Mori T: Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histopathol 1993, 423:265-271.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/7/103/pre-pub